SenoRx, Inc. 

(Public, NASDAQ:SENO)   Watch this stock   
Find more results for SENO
Nov 4, 2009
Q3 2009 SENORX INC Earnings Conference Call
Nov 3, 2009
Q3 2009 SENORX INC Earnings Release
Sep 10, 2009
SENORX INC at Thomas Weisel Partners Healthcare Conference
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin -1.72% -18.65%
Operating margin -1.45% -19.58%
EBITD margin - -16.23%
Return on average assets -2.63% -22.47%
Return on average equity -3.35% -27.78%
Employees 155 -

Address

11 Columbia, Suite A
Aliso Viejo, CA 92656
United States - Map
+1-949-3624800 (Phone)
+1-949-3623519 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

SenoRx, Inc. discussions

  View all discussions »

Description

SenoRx, Inc. develops, manufactures and sells minimally invasive medical devices that are used in the diagnosis of breast cancer. The Company’s initial product focus has been biopsy systems and breast tissue markers, and in January 2008, it launched a radiation balloon catheter for localized partial breast radiation therapy. The sale of disposable products, including its breast biopsy probes, radiation therapy products and tissue markers, accounted for 87.3% of the Company’s revenues during the year ended December 31, 2008. The EnCor system, its flagship product for use in breast biopsy procedures, is a minimally invasive vacuum-assisted breast biopsy system. EnCor allows users to obtain multiple biopsy samples with a single probe insertion. As of December 31, 2008, SenoRx, Inc. had an installed base of 776 EnCor systems and it had sold approximately 205,000 EnCor disposable probes.

Officers and directors

Lloyd H. Malchow
Chairman of the Board, Chief Executive Officer
Age: 55
Bio & Compensation - Reuters
John T. Buhler
President, Chief Operating Officer, Chief Commercial Officer
Age: 48
Bio & Compensation - Reuters
Kevin J. Cousins
Chief Financial Officer, Vice President - Finance
Age: 54
Bio & Compensation - Reuters
Paul Lubock
Senior Vice President, Chief Technology Officer
Age: 53
Bio & Compensation - Reuters
William F. Gearhart
Vice President - Global Marketing and Corporate Development
Age: 61
Bio & Compensation - Reuters
Kim D. Blickenstaff
Director
Age: 56
Bio & Compensation - Reuters
Frederick J. Dotzler
Director
Age: 63
Bio & Compensation - Reuters
John Erb
Director
Age: 60
Bio & Compensation - Reuters
Gregory D. Waller
Director
Age: 59
Bio & Compensation - Reuters
Vickie L. Capps
Director
Age: 47
Bio & Compensation - Reuters